Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin(R) for acromegaly and neuroendocrine tumors

BASEL, Switzerland, NEW YORK and JERUSALEM, Feb. 18, 2013 -- (Healthcare Sales &Marketing Network) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-az-ma) Inc., a privately held biopharma company, announced today that they have entered i... Biopharmaceuticals, Endocrinology, LicensingChiasma, Roche Group, Octreolin, acromegaly
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Acromegaly is a rare disease with vocal changes being a common clinical finding. The authors present a very rare case of an opera singer with undetected acromegaly for years, whose tessiture progressively changed from tenor, to baritone, to bass. We analyze the evolution of vocal parameters over the years and the outcome after surgical treatment.
Source: Journal of Voice - Category: ENT & OMF Authors: Source Type: research
Abstract TheWunderkammer of Schloss Ambras in Innsbruck was one of the first cabinets of curiosities, created in the sixteenth century. Among the many curiosities, the cabinet includes an anonymous Renaissance painting called “Der Riese Hans Kraus” (The giant Hans Kraus). The details suggest us that it could be a representation of an individual affected by acromegaly.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
An 80-year-old man with acromegaly due to a hypoenhancing pituitary microadenoma opted for transsphenoidal resection, but preoperative MRI examination of the sella revealed a left-sided pituitary microadenoma and lobulated polypoid soft tissue masses in the superior nasal cavities arising from the olfactory clefts. What is your diagnosis?
Source: JAMA Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Source Type: research
AbstractBackground and purposeConformal, fractionated radiation therapy (XRT) is variably used as a treatment alternative for active acromegaly patients, usually, after failed pituitary surgery. Our objective was to evaluate the long-term efficacy and safety of XRT using strict criteria of biochemical control.Setting, design, patients, and methodsRetrospective cohort study of 94 patients (73 women, mean age at radiation 53.16  ± 12.9 years) attending a specialized multidisciplinary clinic between 1998 and 2014 with a mean duration of follow-up of 12.9 ± 7.3 years.ResultsA basal growth hormone
Source: Endocrine - Category: Endocrinology Source Type: research
ConclusionsPreoperative medical treatment had no effect on the costs of acromegaly treatment. There was a benefical effect of pre-operative SSA use on early remission in patients with macroadenomas; however, this effect didn ’t persist long term.
Source: Pituitary - Category: Endocrinology Source Type: research
Authors: Dereli S, Özer H, Özer N, Bayramoğlu A, Kaya A Abstract BACKGROUND: In acromegaly patients; it has been observed that heart failure may develop even in the absence of predisposing factors such as hypertension, diabetes mellitus, so a specific acromegalic cardiomyopathy has been suggested. We aimed to evaluate the fQRS frequency in acromegaly patients and the left ventricular (LV) functions of acromegaly patients with fQRS. METHODS: Our study included 60 acromegalic patients. Each patient underwent conventional echocardiography and tissue Doppler imaging. The patients included were separated ...
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research
Publication date: September 2019Source: Materials Science and Engineering: C, Volume 102Author(s): He Gong, Jing Wang, Jue Zhang, Jianbing Wu, Zhaozhu Zheng, Xusheng Xie, David L. Kaplan, Gang Li, Xiaoqin WangAbstractPoly(d,l-lactide-co-glycolide) (PLGA) microspheres have been used as an injectable depot for prolonged release of octreotide (Sandostatin LAR®), a peptide drug for the treatment of acromegaly and gastrointestinal tumors. However, acylation and incomplete release of the encapsulated octreotide, as well as acidic degradation product-induced inflammation are the major challenges hampering widespread clinical ...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
In patients with acromegaly, chronic GH and IGF-I excess commonly causes a specific cardiomyopathy characterized by a concentric cardiac hypertrophy associated with diastolic dysfunction and, in later stages, with systolic dysfunction ending in heart failure in untreated and uncontrolled patients. Additional relevant cardiovascular complications are represented by arterial hypertension, valvulopathies, arrhythmias, and vascular endothelial dysfunction, which, together with the respiratory and metabolic complications, contribute to the development of cardiac disease and the increase cardiovascular risk in acromegaly. Diseas...
Source: Heart Failure Clinics - Category: Cardiology Authors: Source Type: research
by Jaclyn M. Fingerhut, Jessica V. Moran, Yukiko M. Yamashita Intron gigantism, where genes contain megabase-sized introns, is observed across species, yet little is known about its purpose or regulation. Here we identify a unique gene expression program utilized for the proper expression of genes with intron gigantism. We find that twoDrosophila genes with intron gigantism,kl-3 andkl-5, are transcribed in a spatiotemporal manner over the course of spermatocyte differentiation, which spans ~90 hours. The introns of these genes contain megabases of simple satellite DNA repeats that comprise over 99% of the gene loci, and t...
Source: PLoS Genetics - Category: Genetics & Stem Cells Authors: Source Type: research
CONCLUSION: The ICER of pasireotide compared to FG SSA was six times higher than the ICER of pegvisomant vs. FG SSA. Pegvisomant is a more cost-effective alternative for the treatment of acromegaly in FG SSA-resistant patients in the Spanish NHS. PMID: 31055976 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
More News: Acromegaly | Endocrinology | Marketing | Neurology | Pharmaceuticals